INTRODUCTION
The first guideline 1 published by the American Society of Clinical Oncology (ASCO) provided recommendations on uses of hematopoietic colonystimulating factors (CSFs), including primary prophylaxis of fever and neutropenia (FN) in patients undergoing chemotherapy for malignancy if their risk was Ն 40%. ASCO has updated this guideline periodically, most recently in 2006, 2 when the threshold for primary prophylaxis with a CSF was revised to include patients at Ն 20% risk for FN. Although the CSF guideline is scheduled for another update soon, ASCO has not previously addressed other measures (eg, prophylactic antimicrobial drugs or protective environments) to prevent infection in outpatients who are neutropenic, not yet febrile, and either continue to receive or have recently completed chemotherapy for malignancy. Additionally, a priority-setting exercise of the ASCO Clinical Practice Guidelines Committee (CPGC) selected outpatient management of febrile neutropenia as an important topic for a new guideline.
Managing FN in oncology patients began to change in the late 1960s and early 1970s, when evidence emerged that empiric antibacterial therapy reduced deaths resulting from infection, compared with waiting for results of microbiologic assays. [3] [4] [5] [6] [7] The spectrum of bacterial pathogens most commonly isolated from patients with FN during or after treatment for malignancy shifted from mostly Gram-negative species in the 1960s and 1970s to more Gram-positive species in the 1980s and 1990s. Currently, coagulase-negative staphylococci are the most common species identified in blood cultures, but the frequency of drug-resistant Gram-negative bacterial infections is increasing. However, blood and other cultures are negative and the causative organism and site of infection remain uncertain in many oncology patients with fever. Because infection can progress rapidly and become life threatening if patients are neutropenic, clinical practice guidelines recommend administration of broad-spectrum antibacterials (using monotherapy or a combination regimen) soon (within an hour) after fever is documented. [7] [8] [9] [10] [11] [12] [13] Until the late 1980s and early 1990s, empiric antibacterial therapy was almost invariably administered intravenously (IV) in the hospital if an oncology patient developed FN. Presently, a wider spectrum of disorders than ever before is being managed on an outpatient basis. Potential advantages of outpatient management include increased convenience for patients and their family members, reduced costs of care, and, particularly for those at risk of infection, decreased exposure to hospital-acquired infections, which often may be resistant to the antibiotics used most frequently. Malignancies currently being treated outside the hospital range from adjuvant systemic therapy for breast cancer to postremission consolidation with high-dose cytarabine for acute myeloid leukemia to reduced-intensity conditioning stem-cell transplantation (SCT). Various approaches have been studied to stratify such patients who develop FN by risk for medical complications or death.
14-21 Several of these approaches have been used to select lowrisk patients for early discharge or outpatient therapy, and a number of trials randomly assigning low-risk patients have compared outcomes of inpatient versus outpatient management 14, [21] [22] [23] [24] [25] or oral versus IV antibacterials as empiric therapy. 14, 26, 27 In light of the evidence from such studies, the ASCO CPGC assembled a panel of experts to address the following clinical questions.
GUIDELINE QUESTIONS
A. What interventions are appropriate to prevent infections in patients with a malignancy who have received chemotherapy in an inpatient or outpatient setting and who are, or are anticipated to become, neutropenic as outpatients?
A-1. How should risk of developing a febrile neutropenic episode (FNE) be assessed in such patients who are not yet febrile? What clinical characteristics identify patients who should be offered antimicrobial prophylaxis? A-2. What antimicrobial drug classes should be used to prevent infection in afebrile neutropenic outpatients who should be offered prophylaxis? A-3. What additional precautions are appropriate to prevent exposure of neutropenic but afebrile outpatients with a malignancy to infectious agents or organisms? B. Which patients with a malignancy and febrile neutropenia are appropriate candidates for outpatient management? B-4. What clinical characteristics should be used to select patients for outpatient empiric therapy? B-5. Should outpatients with FN at low risk for medical complications receive their initial dose(s) of empiric antimicrobial(s) in the hospital or clinic and be observed, or can some selected for outpatient management be discharged immediately after evaluation? B-6. What psychosocial and logistic requirements must be met to permit outpatient management of patients with FN? C. What interventions are indicated for patients with a malignancy and febrile neutropenia who can be managed as outpatients? C-7. What diagnostic procedures are recommended? C-8. What antibacterials are recommended for outpatient empiric therapy? C-9. What additional measures are recommended for outpatient management? C-10. How should persistent neutropenic fever (PNF) syndrome be managed?
CLINICAL PRACTICE GUIDELINES
Practice guidelines are systematically developed statements that assist practitioners and patients in making decisions about care. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, flexibility, clarity, multidisciplinary process, review of evidence, and documentation. Guidelines may be useful in producing better care and decreasing cost. Specifically, use of clinical guidelines may provide: 1. Improvements in outcomes 2. Improvements in medical practice 3. A means for minimizing inappropriate practice variation 4. Decision support tools for practitioners 5. Points of reference for medical orientation and education 6. Criteria for self-evaluation 7. Indicators and criteria for external quality review 8. Assistance with reimbursement and coverage decisions 9. Criteria for use in credentialing decisions 10. Identification of areas where future research is needed
METHODS

Panel Composition
An Expert Panel with a spectrum of contributors reflecting private practice oncology, academic hematology/oncology practice, infectious diseases, oncology nursing, and interest group societies and consisting of experts in clinical medicine and research methods relevant to prevention and treatment of infection in patients with neutropenia after therapy for a malignancy as well as a patient representative met once in person to discuss evidence from a systematic review and draft recommendations on outpatient management. The Panel interacted by e-mail and telephone to revise and finalize recommendations and to prepare drafts of the full guideline and additional documents and tools. Panel members and their expertise are listed in Appendix Table A1 (online only).
Literature Review and Analysis
Literature search strategy. The MEDLINE database was searched using PubMed for relevant evidence published from 1987 through the end of April 2011. The search included terms for malignant diseases linked to terms for neutropenia, fever, or infection and to terms for clinical trials, systematic reviews, meta-analyses, or clinical guidelines. Data Supplement 1 provides the full search strategy (online at www.asco.org/guidelines/outpatientfn). One reviewer selected articles for full-copy retrieval and consulted a Panel cochair when potential relevance was uncertain. Reference lists of articles retrieved in full copy were searched for other relevant reports. Panel members provided additional references from personal files.
Inclusion and exclusion criteria. Articles were selected for inclusion in the systematic review if they were fully published English-language reports on: antimicrobials for prophylaxis of infection in oncology outpatients with neutropenia from chemotherapy, development and/or validation of methods to stratify risk of complications in oncology patients with FN, empiric antimicrobial therapy for oncology outpatients with FN, or direct comparisons of outcomes for inpatient versus outpatient management of oncology patients with FN. For clinical questions addressing antimicrobials for prophylaxis of infection or as empiric therapy for FN, study selection criteria limited inclusion to reports from randomized controlled trials (RCTs) of adult human participants, systematic reviews and meta-analyses of RCTs, or evidence-based clinical practice guidelines. Prospective or retrospective cohort studies, casecontrol studies, and case series were included for questions addressing risk stratification or direct comparison of inpatient versus outpatient management. Meeting abstracts, letters, commentaries, editorials, case reports, and nonsystematic (narrative) reviews were excluded from evidence tables for all questions.
Data extraction. For studies on afebrile neutropenic outpatients, primary outcomes included: 1) febrile episodes and 2) infections, whereas secondary outcomes included infection-related mortality. For studies on outpatients with FN, primary outcomes included: 1) empiric treatment success (defined as recovery from FN without medical complications) and 2) overall and infection-related mortality, whereas secondary outcomes included: 1) defervescence without regimen change, 2) time to defervescence, 3) complications from infection, and 4) relapsed or recurrent fever. Additional secondary outcomes relevant to both sets of studies included: 1) hospital admissions, 2) duration of hospital stay, and 3) adverse effects of antimicrobials. Data were extracted directly into evidence tables (see Data Supplement  Tables DS-3 to DS-9; online at www.asco.org/guidelines/outpatientfn) by one reviewer and checked for accuracy by a second reviewer. Disagreements were resolved by discussion and by consultation with Panel cochairs if necessary.
Definition of Terms
For purposes of this guideline, the Panel defined neutropenia as an absolute neutrophil count (ANC) Ͻ 1,000/L (equivalent to Ͻ 1.0 ϫ 10
Guideline Policy
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RESULTS
This clinical practice guideline addresses three overarching questions (Table 1) , each subdivided into three or four clinical questions. Recommendations A-1 to A-3 address clinical questions relevant to the first overarching question on preventing infection in oncology outpatients who have or are expected to develop neutropenia but are without fever or evidence of infection. Recommendations B-4 to B-6 address the second overarching question on selecting patients with FN who can safely be managed as outpatients. Recommendations C-7 to C-10 focus on interventions and strategies to safely manage oncology patients with FN outside the hospital.
Other Guidelines and Consensus Statements
Other organizations have published guidelines or consensus statements addressing clinical questions also addressed here. These include guidelines on managing FN in patients with cancer from the Japan Febrile Neutropenia Study Group, 9 the European Society of Medical Oncology (ESMO), 10 and an Australian consensus panel. 13, 21, 28, 29 Additionally, the National Comprehensive Cancer Network (NCCN) has published guidelines on prevention and treatment of cancer-related infections, 11 and the Infectious Disease Society of America (IDSA) 7, 12 and the Infectious Diseases Working Party of the German Society of Hematology and Oncology 8 have published guidelines on uses of antimicrobial drugs in neutropenic patients with cancer. The Panel has evaluated the recommendations of these organizations and found them to be generally consistent with recommendations in this ASCO clinical practice guideline. Specific differences are highlighted and discussed in the Literature Review and Discussion sections that follow each recommendation in the full guideline (online at www.asco.org/guidelines/outpatientfn). Table 1 lists the 10 clinical questions addressed in this practice guideline and the recommendation of the Panel for each. Below are brief summaries of the literature review and discussion for each recommendation. See the full guideline online for detailed analysis and discussion of the evidence.
GUIDELINE RECOMMENDATIONS
Literature Review and Discussion for Clinical Question A-1
Because evidence was unavailable from trials limited to outpatients, Recommendations A-1a to A-1g are based on evidence from studies on inpatients or mixed populations (see the full guideline online) and Panel members' expert opinion. Table 2 lists variables shown to influence risks in one or more studies, grouped by characteristics of: patients and their health status, their underlying malignancy, and the chemotherapy regimen they are receiving. Most studies cited in Table 2 used multivariable regression analysis to identify independent predictors of FNE risk. Some of the cited studies 34-37,42,47,52 and others 55,56 have also developed and tested models to predict likelihood of an FNE in the first or a subsequent chemotherapy cycle. However, the literature search found no data from prospective studies that used validated models, checklists, or scores to select neutropenic but afebrile oncology outpatients for prophylaxis with antibacterial drugs and compared outcomes (eg, rates of FNEs or documented infection) with controls. Thus, on the basis of members' expert opinion, the Panel recommends (A-1a) that patients starting a new chemotherapy regimen undergo an individualized but systematic assessment of risk for an FNE that weighs the factors listed in Table 2 and includes consultation with local infectious disease experts as needed.
Guidelines from ASCO 2 and other organizations 11,12,54,57-59 recommend primary prophylaxis with a CSF for patients with a high risk of an FNE based on age, medical history, disease characteristics, and myelotoxicity of their chemotherapy regimen. Readers are referred to these guidelines for review and discussion of the evidence supporting this recommendation and for recommendations on selecting patients likely to benefit from primary prophylaxis. Table 1 in the ASCO guideline 2 also includes a list of commonly used regimens by malignancy, with data on incidence of hematologic toxicities including neutropenia and FNEs (available online at www.asco.org/guidelines/ wbcgf). Note that antibacterial and antifungal prophylaxis would generally not be indicated when CSF prophylaxis effectively reduces the depth and duration of neutropenia.
Recommendation A-1b (on patient selection for antibacterial prophylaxis) is based on: a systematic review 60 of metaanalyses of RCTs of interventions for febrile neutropenia, the five 61-66 meta-analyses it reviewed of antibacterial prophylaxis, two updates 67,68 of a Cochrane review, and two other meta-analyses 69, 70 and a systematic review. 71 Although the preponderance of data from these meta-analyses and the RCTs they included showed that antibacterial prophylaxis decreased mortality when compared with pooled controls administered either placebo or no treatment, a majority of included patients were undergoing either remission induction (or reinduction) for hematologic malignancy (mostly acute leukemia) or hematopoietic SCT (HSCT) and thus were at relatively high risk for an FNE and infection. Lacking robust evidence that antibacterial prophylaxis improves outcomes for patients with neutropenia at low risk for an FNE, and in light of concerns raised in reviews 62,64-68,71-73 and other guidelines 7, 11, 12 ,29 that routine use (or overuse) of antibacterial What clinical characteristics identify patients who should be offered antimicrobial prophylaxis? Recommendation A-1. Because evidence to address this question was unavailable from trials limited to outpatients, the Panel considered evidence from studies on inpatients or mixed populations and recommends the following, based on such evidence and members' expert opinion: A-1a. FNE risk should be systematically assessed (in consultation with infectious disease specialists as needed), including patient-, cancer-, and treatment-related factors (see Table 2 ); G-CSF prophylaxis should be used before neutropenia develops for patients who meet criteria specified in the ASCO WBC growth factors guideline
A-1b. Clinicians should consider antibacterial prophylaxis only for patients expected to experience profound neutropenia (defined as ANC however, outpatient management may be acceptable for carefully selected patients; when considering a patient with an FNE for outpatient management, the Panel recommends beginning the evaluation with a systematic risk assessment using a validated index; the MASCC risk index (see Table 3 ) has been evaluated most thoroughly of the available risk indices for adults; Talcott's rules have also been validated in prospective studies; however, the FNE should be managed in the hospital if the clinician has any reservations with respect to the accuracy of an index for an individual, even if the patient is classified as low risk (MASCC score Ն 21 or Talcott group 4); Table 4 lists additional factors to take into account when assessing risk for medical complications in the setting of outpatient FNE management; patients meeting any of the criteria listed in Table 4 , those with MASCC score Ͻ 21, or those in Talcott groups 1 to 3 should not be managed as outpatients; moreover, neither a currently available risk index nor the criteria in Table 4 should substitute for clinical judgment when deciding whether a
given patient with an FNE should be admitted to the hospital for inpatient management B-5. Should outpatients with FN at low risk for medical complications receive their initial dose(s) of empiric antimicrobial(s) in the hospital or clinic and be observed, or can some selected for outpatient management be discharged immediately after evaluation? Recommendation B-5. The duration of observation before outpatients were discharged varied considerably among studies that directly compared inpatient versus outpatient empiric therapy or oral versus IV regimens in outpatients; lacking evidence from direct comparisons, the Panel relied on members' expert opinion to recommend that the first dose of empiric therapy be administered within 1 hour after triage from initial presentation in the clinic, emergency room, or hospital department, after fever has been documented in a neutropenic patient and pretreatment blood samples have been drawn; similarly, the Panel recommends that patients identified as low risk and selected for outpatient management be observed for at least 4 hours before discharge to verify they are stable and can tolerate the regimen they will receive B-6. What psychosocial and logistic requirements must be met to permit outpatient management of patients with fever and neutropenia? Recommendation B-6. Because direct comparative evidence was unavailable for any of these factors, the Panel relied on members' expert opinion to recommend that an oncology patient with FN during or after chemotherapy meet each of the following criteria to receive empiric therapy as an outpatient:
a. Residence prophylaxis may increase spread of resistant strains, the Panel recommends that clinicians limit use of antibacterial prophylaxis to patients at high risk for an FNE. Recommendation A-1c (on antifungal prophylaxis) is based on systematic reviews 60,73-75 and meta-analyses [76] [77] [78] [79] [80] [81] of RCTs that enrolled patients with or expected to develop neutropenia from treatment for malignancy and compared outcomes of systemic antifungal prophylaxis versus controls administered placebo, no treatment, or a nonabsorbable oral antifungal. Although the three most relevant meta-analyses 77, 79, 81 reported that when compared with controls, systemic antifungal prophylaxis significantly decreased mortality attributed to fungal infections and also improved other outcomes, most patients randomly assigned in the RCTs pooled for meta-analysis were at Ն 6% risk for invasive fungal infection (IFI) resulting from HSCT, induction chemotherapy for acute leukemia, or other treatments that caused long durations of profound neutropenia. No trials included in these meta-analyses were limited to patients with solid tumors undergoing conventional-dose chemotherapy with or without biologics. Thus, in agreement with other guidelines, 11,12 the Panel recommends limiting antifungal prophylaxis to patients at substantial risk for IFI (Ͼ 6% to 10%) from regimens likely to decrease ANC to Ͻ 100/L for Ն 7 days.
Lacking evidence from RCTs, Recommendation A-1d is based on retrospective observational studies [82] [83] [84] [85] [86] and expert opinion; Panel members agreed that Pneumocystis prophylaxis should be limited to patients receiving chemotherapy regimens associated with Ͼ 3.5% risk for Pneumocystis pneumonia. A systematic review 87 of Pneumocyctis in immunocompromised patients not infected with HIV reported that Pneumocyctis infection rates without prophylaxis were Ն 3.5% among patients treated with allogeneic HSCT or induction therapy for acute leukemia or rhabdomyosarcoma but were Ͻ 3.5% among other oncology patients (eg, those with Hodgkin lymphoma or CNS tumors or those receiving long-term corticosteroid therapy). Evidence from reviews 73,88-90 of prospective controlled studies supported use of a nucleoside analog to prevent hepatitis B virus (HBV) reactivation in patients at known risk (Recommendation A-1e; primarily chronic inactive carriers; see full guideline online for detailed discussion). On the basis of a Cochrane review 91 and data summarized in other guidelines 11,12,92-96 and elsewhere, 73 there was insufficient evidence of clinical benefit from nucleoside analog prophylaxis against reactivation of latent herpes simplex or herpes zoster virus in patients receiving conventional-dose regimens for solid tumors or lymphoma. Thus, the Panel recommends (Recommendation A-1f) limiting such treatment to those undergoing more-intensive therapies (eg, HSCT or remission induction for acute leukemia). Finally, Recommendation A-1g on seasonal influenza immunization is based on systematic reviews 97-104 summarizing evidence of protective responses to and safety of influenza vaccine in oncology patients.
Literature Review and Discussion for Clinical Question A-2
Evidence for question A-2 also was unavailable from trials limited to outpatients; Recommendations A-2a to A-2f are based on evidence from studies on inpatients or mixed populations and Panel members' expert opinion. Similarly, because evidence was unavailable to directly compare different durations and timing (start and stop dates) for prophylactic therapies, the suggestions of the Panel on timing and duration (see full guideline online) reflect members' experience and expert opinion.
Recommendation A-2a rests primarily on meta-analyses from a Cochrane review, 64,65,68 which showed that systemically absorbed oral fluoroquinolones are the most tolerable choice for prophylaxis in neutropenic oncology patients and are equally protective whether used alone or combined with other antibacterials active against Grampositive organisms. As detailed under Recommendation A-1b in the full guideline online, the Panel recommends limiting antibacterial prophylaxis to oncology outpatients anticipated to experience profound neutropenia for Ն 7 days in association with severe mucositis or with other risk factors listed in Table 2 .
Evidence from other meta-analyses 77,79-81,105,106 supported Recommendation A-2b for use of an orally administered triazole antifungal drug (eg, fluconazole) to prevent invasive Candida infections in patients with Ͼ 10% risk or a mold-active triazole (eg, itraconazole oral solution) if aspergillosis risk is Ͼ 6%. Again, risks rarely reach these levels unless patients are receiving regimens likely to cause profound neutropenia (ANC Ͻ 100/L) for Ն 7 days. A systematic review and meta-analysis of RCTs 87, 107 supported Recommendation A-2c on use of trimethoprim-sulfamethoxazole to prevent Pneumocystis pneumonia in immunocompromised patients not infected by HIV. The Panel recommends use of lamivudine for HBV prophylaxis (Recommendation A-2d); systematic reviews 73,89,90 suggested it is the only drug available to treat active HBV infection that also has been studied in an RCT to prevent HBV reactivation in oncology patients at risk. A Cochrane review 91 reported that acyclovir was the only nucleoside analog tested in placebo-controlled trials as prophylaxis against reactivation of herpesviruses in oncology patients at risk (Recommendation A-2e); meta-analyses showed acyclovir decreased both oral lesions and viral isolates. Recommendation A-2f on use of inactivated trivalent influenza vaccine is based on a Cochrane review of RCTs of viral vaccines for patients with hematologic malignancies 103 and agrees with other guidelines.
11,12,91,108-12
Literature Review and Discussion for Clinical Question A-3
Direct evidence from RCTs was lacking for an impact on patient outcomes of certain nonpharmacologic interventions and precautions used to minimize exposure of neutropenic but afebrile oncology patients to infection; Recommendations A-3a and A-3b are based on Panel members' experience and expertise. Recommendation A-3a on handwashing reflects the endorsement by the Panel of practices deemed prudent by a panel of the US Centers for Disease Control.
113-15 The recommendation to avoid environments with high spore counts (Recommendation A-3b) rests on retrospective reports 116-20 of risks associated with such sites and the opinion of the Panel on prudent practice. Evidence from RCTs and other comparative studies suggested no effect on health outcomes from routine use of the interventions considered in Recommendation A-3c. A systematic review 121 reported that routine use of high-efficiency particulate air (HEPA) filters did not decrease mortality or fungal infections. An RCT on well-fitting respiratory masks, 122 a nonrandomized study of footwear exchange, 123 and several RCTs on dietary interventions 39,124-26 also reported no significant effects on outcomes.
Literature Review and Discussion for Clinical Question B-4
The Panel needed to evaluate two separate bodies of evidence to develop its recommendation on selecting patients for outpatient management. The first studied outcomes of empiric therapy for an FNE to derive and validate risk assessment tools but enrolled mostly inpatients. The second directly compared outcomes of inpatient versus outpatient management of an FNE in patients deemed at low risk for medical complications. The first group included 16 reports from 15 studies on stratifying risk for medical complications in adult oncology patients with FN from chemotherapy (see Data Supplement Tables  DS-3 and DS-4 for extracted data); the Multinational Association for Supportive Care in Cancer (MASCC) risk index ( show that the MASCC index has been studied in more patients (N ϭ 2,582) and FNEs (N ϭ 2,758), with performance characteristics as good as or better than those of alternatives (sensitivity, 71% to 95%; specificity, 58% to 95%; positive predictive value, 84% to 98%; negative predictive value, 36% to 86%). Talcott's rules 44, 45 provide the only other prospectively validated stratification tool and classify outpatients at FNE onset without either serious comorbidity or uncontrolled cancer (ie, those in group 4) as low risk.
The second group included 10 studies that directly compared outcomes of management in versus out of the hospital for adult oncology patients with FN considered at low risk for complications (see Data Supplement Tables DS-5 and DS-6 for extracted data). These included four RCTs 136-139 (one used Talcott's rules, whereas none used the MASCC score, to identify low-risk patients), four prospective but nonrandomized studies 127, 129, 140, 141 (each required a MASCC score Ն 21 for outpatient management), and two retrospective studies.
142,143 Data reported from all 10 studies (pooled N ϭ 1,423) showed generally high rates of successful empiric therapy (approximately 80% to Ͼ 90%), with no statistically significant differences between outpatient and inpatient arms and few deaths in the outpatient arms. The Panel concluded that at best, results of these studies provide evidence for the safety and efficacy of outpatient empiric therapy in carefully and systematically selected adults with FN from cancer chemotherapy deemed at low risk for medical complications.
However, the optimal strategy to select low-risk patients for management of an FNE outside the hospital is inadequately informed by available evidence and remains somewhat uncertain because each validated method misclassifies some high-risk patients. Pooled data (Data Supplement Table DS-4) showed that serious complications developed in up to 11% of patients classified as low risk by MASCC score Ն 21 and in 7% of patients in Talcott's group 4. Thus, the Panel recommends managing certain patients in the hospital even if they are classified as low risk by either method. Among these are patients with a major abnormality (or significant clinical worsening since the most recent chemotherapy or onset of neutropenia) with respect to any of the following: organ dysfunction, comorbid conditions, vital signs, clinical signs or symptoms, documented anatomic site of infection (as defined by the Immunocompromised Host Society 144 ), laboratory data, or imaging data. The Panel also reviewed clinical criteria excluding patients from studies that compared inpatient versus outpatient management (Data Supplement Tables DS-5 and DS-6) or oral versus IV regimens for outpatient empiric therapy (Data Supplement Tables  DS-7 and DS-8; see Recommendation C-8) among oncology patients with low-risk FN. Table 4 compiles these clinical exclusion criteria by organ system and provides additional details on factors that may be considered major abnormalities. The Panel recommends inpatient management of empiric therapy for an FNE if any of these factors apply.
Literature Review and Discussion for Clinical Question B-5
The literature search did not find any studies that directly compared outcomes of immediate versus delayed discharge or of different observation periods before discharge for outpatient empiric therapy for low-risk FN. Initial antibacterial doses were administered before discharging outpatients in all studies that compared empiric therapy in versus out of the hospital for patients with low-risk FN, with intervals from first dose to discharge ranging from immediate to 48 to 72 hours (Data Supplement Table DS-5). Similarly, intervals from first dose to discharge ranged from 2 to 72 hours among most RCTs that compared oral versus IV regimens for outpatient empiric therapy; only two discharged patients before their first dose and immediately after random assignment (Data Supplement Table DS-7) .
Nevertheless, on the basis of members' expert opinion, the Panel recommends as prudent routine practice the following procedures that were consistently or commonly followed in most studies. Nearly all studies required that fever be documented and samples (eg, of blood and other fluids) be obtained for culture and microbiologic assays before patients received their first dose. In agreement with an international guideline panel of the Surviving Sepsis Campaign, 145 the Panel also recommends administering the first dose of empiric initial antibacterial therapy as soon as possible after triage (Յ 1 hour seems an achievable and prudent performance standard) from presentation with FN. Most studies also specified that patients' clinical stability and tolerance of oral medications should be verified before they were discharged for outpatient management of FN. Lacking evidence directly comparing different observation intervals, the Panel recommends observation for Ն 4 hours after the initial dose as prudent practice before discharge to continue empiric therapy as an outpatient.
Literature Review and Discussion for Clinical Question B-6
The literature search did not find any studies that directly compared outcomes of outpatient empiric therapy for FN in patients who did versus did not meet any of the psychosocial and logistic requirements in Recommendation B-6. Nevertheless, studies comparing inpatient versus outpatient empiric therapy (Data Supplement Table DS-5) or oral versus IV therapy for outpatients (Data Supplement Table DS-7) limited eligibility to patients with FN who met all or most of these criteria. On the basis of members' expert opinion, the Panel recommends treatment in the hospital 12,127 †Burden of febrile neutropenia refers to the general clinical status of the patient as influenced by the febrile neutropenic episode. It should be evaluated on the following scale: no or mild symptoms (score of 5), moderate symptoms (score of 3), and severe symptoms or moribund (score of 0). Scores of 3 and 5 are not cumulative.
‡Chronic obstructive pulmonary disease means active chronic bronchitis, emphysema, decrease in forced expiratory volumes, or need for oxygen therapy and/or steroids and/or bronchodilators requiring treatment at the presentation of the febrile neutropenic episode.
§Previous fungal infection means demonstrated fungal infection or empirically treated suspected fungal infection.
for patients who do not meet one or more of the listed criteria because the only evidence for safety and efficacy of outpatient therapy is from studies conducted in patients who satisfied these requirements.
Literature Review and Discussion for Clinical Question C-7
The literature search did not find direct comparative evidence on the clinical utility of different diagnostic procedures for Impaired renal function (creatinine clearance Յ 30 mL/min) or oliguria or clinically relevant worsening renal function (as determined by the treating physician) New onset of gross hematuria Urinary obstruction or nephrolithiasis Clinically relevant dehydration Clinically relevant electrolyte abnormalities, acidosis or alkalosis (requiring medical intervention) Other significant comorbidity Presence of a major abnormality in regard to: organ dysfunction, comorbid conditions, vital signs, clinical signs or symptoms, laboratory data, or imaging data Any relevant clinical worsening (as determined by the treating physician) of: organ dysfunction, comorbid condition, vital signs, clinical signs or symptoms, laboratory data, or imaging data Pregnant or nursing Need for IV pain control Fractures, injuries, or need for emergent radiation therapy Abbreviations: ANC, absolute neutrophil count; FN, fever and neutropenia; Hb, hemoglobin; Hct, hematocrit; IV, intravenous; MASCC, Multinational Association for Supportive Care in Cancer; Pa CO 2 , arterial carbon dioxide tension; SIRS, Systemic Inflammatory Response Syndrome; ULN, upper limit of normal.
‫ء‬ This is not a comprehensive list. Less-severe clinical conditions or abnormalities may require hospitalizations as suggested in the text and summary of the full guideline online. This list does not replace the need for clinical judgment while making decisions on outpatient versus inpatient management of FN for individual patients.
†New onset of minimal symptoms of urinary tract infection and sinusitis may be excluded from this requirement in most settings with neutropenia Ͻ 7 days and absence of fungal infection.
‡Severe sepsis is a syndrome defined by the presence of evidence for SIRS (defined by Ն two of the following criteria: body temperature Ͼ 38°C or Ͻ 36°C, heart rate Ͼ 90 beats/minute, respiratory rate Ͼ 20/minute, Pa CO 2 Ͻ 32 mmHg, an alteration in the total leukocyte count to Ͼ 12 ϫ 10 9 /L or Ͻ 4 ϫ 10 9 /L, or the presence of Ͼ 10% band neutrophils in the leukocyte differential) plus evidence of infection, plus evidence of end-organ dysfunction (altered mental status, hypoperfusion ͓defined by hypotension (systolic blood pressure Ͻ 90 mmHg, mean arterial pressure Ͻ 70 mmHg, systolic blood pressure decrease of Ͼ 40 mmHg, or Ͻ two standard deviations below the mean for age), by an elevated serum lactate Ͼ 4 mmol/L, or by oliguria (urine output Ͻ 0.5 mL/kg/hour)͔, and/or hypoxia).
oncology patients who present with FN. On the basis of members' expert opinion and experience, the Panel considers bacterial infection the most reasonable assumption and likeliest source of such patients' fever if an alternative explanation cannot be documented. For that reason, the Panel recommends that the diagnostic approach seek to identify infecting organisms and establish a microbiologic diagnosis if at all possible and thoroughly evaluate possible sites of infection to establish a clinical diagnosis (see the full guideline online for the list of elements the Panel recommends to include in evaluating oncology patients who present with a new FNE).
Literature Review and Discussion for Clinical Question C-8
Evidence from randomized trials of empiric therapy for FN in hospitalized oncology patients supports early use of broadspectrum antibacterial drugs to decrease mortality and morbidity (see full guideline online for references to relevant reviews and other guidelines). Most RCTs that compared outcomes of different drugs or regimens for empiric therapy also enrolled mostly hospitalized patients not selected or stratified by risk for complications.
Results from 10 meta-analyses 26,27,146-156 of comparative RCTs relevant to both inpatients and outpatients are summarized in Data Supplement Table DS-9. Important findings from these metaanalyses include: similar safety and efficacy with oral versus IV regimens as initial empiric therapy 26, 27 ; no better survival or therapeutic success, yet increased toxicity from adding an aminoglycoside to a broad-spectrum ␤-lactam active against Pseudomonas ; and no decrease in overall or infection-related mortality or fever duration from adding a drug targeted against Gram-positive bacteria (eg, vancomycin) to a ␤-lactam with or without an aminoglycoside. 148 Although outpatient IV therapy is widely available, oral drugs are more convenient, less costly, and preferred by many patients and clinicians to treat low-risk FN in the outpatient setting.
142,157 Because the literature search did not identify any trials that directly compared different oral regimens for outpatient empiric therapy, the recommendations of the Panel on choice of an oral regimen relied on indirect comparison of results from separate RCTs. Eight of nine RCTs that compared oral versus IV antibacterials as outpatient empiric therapy for low-risk FN used a fluoroquinolone for patients in the oral arm (Data Supplement Tables DS-7 and DS-8). Similarly, most studies on inpatient versus outpatient empiric therapy (Data Supplement Tables DS-5 and DS-6) used an oral fluoroquinolone for the outpatient arms. However, few studies used fluoroquinolone monotherapy exclusively throughout, and the largest and most convincing body of evidence on the safety and efficacy of oral outpatient empiric therapy for FN is from studies that used ciprofloxacin plus amoxicillin-clavulanate. Thus, the Panel recommends this as a firstchoice oral regimen in empiric therapy for low-risk FN in oncology outpatients. Also, in agreement with other guidelines, 11,12 the Panel advises against use of a fluoroquinolone alone as initial empiric therapy for outpatient management of FN. If circumstances rule out or argue against selection of this regimen for initial empiric therapy (eg, penicillin allergy), the Panel recommends ciprofloxacin plus clindamycin 158 as an alternative. Table 5 summarizes the recommendations of the Panel on initial empiric antibacterial therapy for oncology outpatients with FN under various circumstances but considered at low risk for medical complications. Note also that patients infected by Gram-negative pathogens resistant to both fluoroquinolones and ␤-lactams should be treated as inpatients with an IV regimen that likely requires multiple doses per day (eg, meropenem every 8 hours or piperacillin plus tazobactam every 6 hours).
Literature Review and Discussion for Clinical Question C-9
The literature search did not identify any studies directly comparing outcomes for oncology outpatients with FN managed with versus without specific logistic measures or with different frequencies of contact or evaluation. Because relevant evidence was lacking, the Panel examined follow-up and evaluation procedures for outpatients in studies that compared inpatient versus outpatient therapy (Data Supplement Tables DS-5 and DS-6) or oral versus IV regimens in outpatients (Data Supplement Tables DS-7 and DS-8). Panel members relied on their expert opinion and experience to devise and agree on the listed procedures they judged to be prudent and sensible for follow-up and evaluation of oncology outpatients with an FNE, based on those described in the Methods sections of the studies cited in Data Supplement Tables DS-5 to DS-8. 
Literature Review and Discussion for Clinical Question C-10
Evidence on outcomes of alternative strategies to manage PNF syndrome was outside the scope of the systematic review conducted for this guideline. It suffices to say that Panel members agreed unanimously with the need to re-evaluate and possibly hospitalize patients whose fever does not resolve after 2 to 3 days of empiric therapy with a broad-spectrum regimen. The same approaches to evaluation and subsequent treatment of patients with PNF seem appropriate whether patients received initial empiric therapy in the hospital or as outpatients. More detailed recommendations are available in guidelines from other organizations.
11,12
PATIENT AND CLINICIAN COMMUNICATION
Successful management of FNEs in adult oncology outpatients requires that patients and their family or volunteer caregivers be educated to promptly recognize and act on signs and symptoms of possible infection. Effective education about monitoring body temperature and other symptoms of infection is vital. Additionally, communications should acknowledge and address the reality that many patients are reluctant to seek help outside of office hours. It is essential that patients and caregivers receive clear written instructions on when and how to contact health care practitioners. Patients and their caregivers should be informed of evidence-based infection control guidelines to minimize unnecessary restrictions. Instructions should be tailored to individual needs according to health literacy and numeracy, living circumstances, language barriers, and decision-making capacity. Written and/or electronic copies of FN management plans should be provided so that subsequent care decisions are based on adequate information.
HEALTH DISPARITIES
This guideline provides expert recommendations on the best practices to prevent infection and manage FN in oncology outpatients. It is important to note that many patients in the United States have limited access to medical care, including some members of racial and ethnic minorities, those of lower socioeconomic status, and those living some distance from appropriate treatment facilities. Members of some groups suffer disproportionately from comorbidities, experience more-substantial obstacles to receiving care, are more likely to be uninsured, and are at greater risk of receiving care of poor quality than other Americans. Awareness of these disparities in access to care should be considered in the context of this clinical practice guideline, and health care providers should strive to deliver the highest level of cancer care to these vulnerable populations.
Although experts agree that timely assessment and administration of initial empiric antibacterial therapy to febrile neutropenic patients with cancer is important, the time from initial triage to first antibiotic may be longer for those with disparities in access to care. Note also that ethnic neutropenia occurs across populations of African descent, although the impact this entity may have on the management of neutropenia and FN is uncertain.
FUTURE DIRECTIONS
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. One major limitation of the evidence available to inform this guideline is the absence of data from RCTs that either studied the net effect on health outcomes or compared the efficacy and safety of alternative regimens for antibacterial prophylaxis specifically in afebrile neutropenic outpatients. Another is the lack of well-validated scales or models to assess and stratify risk for complications and mortality and thus identify afebrile outpatients with neutropenia most likely to benefit from prophylactic antibiotics. Although the MASSC scale is a validated tool to identify patients at low risk for medical complications among those with FN,thefalse-positiverateintrialsreviewedforthisguidelineshowsthereis a definite need for improvement. Future research is needed to develop and validate a modified MASCC score with improved sensitivity and specificity. Also needed are better data to define a minimal observation period in the hospital or clinic before discharging patients to continue empiric therapy for FNEs at home. The Panel sees a need for future research to fill these gaps.
ADDITIONAL RESOURCES
The full guideline, with a comprehensive discussion of the literature, more detail on literature search methodology, a full reference list, evidence tables, and clinical tools and resources are found at www.asco .org/guidelines/outpatientfn. Patient information is available there and at www.cancer.net.
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